Brief: Revive Therapeutics Advances Research Program Of Cannabinoid-Based Therapies Targeting Liver Diseases
30/01/2018 12:01
Jan 30 (Reuters) - Revive Therapeutics Ltd RVV.V :
* REVIVE THERAPEUTICS ADVANCES RESEARCH PROGRAM OF
CANNABINOID-BASED THERAPIES TARGETING LIVER DISEASES
* REVIVE THERAPEUTICS LTD - RESEARCH WILL BE OVERSEEN BY
SANYAL
BIOTECHNOLOGY LLC COMPANY'S STRATEGIC RESEARCH PARTNER FOR LIVER
DISEASES
Source text for Eikon: ID:nGNXOMSQRa
Further company coverage: RVV.V
((Bangalore.newsroom@thomsonreuters.com; ;))
Recent news on Revive Therapeutics
See all newsBrief: Revive Therapeutics Provides Update Of Key Nerve Agent Countermeasure Study
Brief: Revive Therapeutics Provides Update Of Key Nerve Agent Countermeasure Study
Brief: Revive Therapeutics Announces Closing Of Second Tranche Of Private Placement
Brief: Revive Therapeutics Nears Completion Of Key Nerve Agent Countermeasure Study With Canadian Department Of National Defence
Brief: Revive Therapeutics Provides Update On Research Study Evaluating Bucillamine For Nerve Agent Exposure